Well, well, well. Now we all know why the share price has been manipulated down. Wonder if toothless ASIC will investigate this? Let's see how those selling recently benefit from the CR.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%